Stoke Therapeutics (STOK) Short-term Investments (2021 - 2026)

Stoke Therapeutics' Short-term Investments history runs 6 years deep, the most recent figure standing at $187.9 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 127.72% year-over-year to $187.9 million in Q1 2026; TTM through Mar 2026 was $187.9 million, a 127.72% increase from a year earlier, with the FY2025 full-year figure at $200.4 million, up 125.44% from the prior year.
• Short-term Investments retreated to $187.9 million in Q1 2026 per STOK's latest filing, from $200.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $209.1 million in Q1 2022 and bottomed at $75000.0 in Q2 2024.
• The 5-year median for Short-term Investments is $102.5 million (2022), against an average of $105.0 million.
• Across the five-year window, Short-term Investments plunged 99.81% in 2024 and surged 219788.0% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $116.0 million in 2022, then slumped by 91.42% to $10.0 million in 2023, then soared by 793.45% to $88.9 million in 2024, then jumped by 125.44% to $200.4 million in 2025, then decreased by 6.27% to $187.9 million in 2026.
• Per Business Quant, the three latest STOK Short-term Investments figures stand at $187.9 million (Q1 2026), $200.4 million (Q4 2025), and $164.9 million (Q3 2025).